Molecular Subtype
HER2-Positive Gastric Adenocarcinoma
CI-CAN-00007796Explore in graph →
15 active trials
- NCIt
- C227256
Loading cancer entity…
Loading cancer entity…
Molecular Subtype
CI-CAN-00007796Explore in graph →
Clinical trials
43 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (7)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05955833 | 89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study(HER Image) | completed | N/A | 6 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04082364 | Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer(MAHOGANY) | completed | Phase 2 / Phase 3 | 82 | MacroGenicsINDUSTRY | 9 | Jun 8, 2025 |
| clinicaltrials |
| NCT04319757 | ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | completed | Phase 1 | 12 | Acepodia Biotech, Inc.INDUSTRY | 2 | Dec 5, 2024 | clinicaltrials |
| NCT03330561 | PRS-343 in HER2-Positive Solid Tumors | completed | Phase 1 | 85 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03650348 | PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors | completed | Phase 1 | 41 | Pieris Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 22, 2024 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03409848 | Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma(INTEGA) | completed | Phase 2 | 97 | AIO-Studien-gGmbHOTHER | 1 | May 18, 2022 | clinicaltrials |
| NCT03319459 | FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | completed | Phase 1 | 44 | Fate TherapeuticsINDUSTRY | 1 | Nov 22, 2021 | clinicaltrials |
| NCT04920747 | Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients(TandHER) | completed | — | 65 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jun 10, 2021 | clinicaltrials |
Data updated 22 days agoSource updated May 27, 2026source: clinicaltrials